SCHEMBL4348476

SCHEMBL4348476

O=C1N=C(N2CCN(c3ccccc3)CC2)SC1=Cc1ccc(Br)cc1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 1/20 0.78
ALDH1A1 P00352 5/20 0.67
MAPT P10636 8/20 0.65
L3MBTL1 Q9Y468 2/20 0.65
HPGD P15428 2/20 0.65
SENP1 Q9P0U3 1/20 0.64
KMT2A Q03164 4/20 0.63
MEN1 O00255 3/20 0.63
POLB P06746 2/20 0.63
GRIN1 Q05586 3/20 0.61
GRIN2B Q13224 3/20 0.61
HTT P42858 2/20 0.59
RAB9A P51151 1/20 0.56
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54
MAPK1 P28482 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ENPP2 Q13822 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348473 1.00 DCTPP1 (0.78) DCTPP1ALDH1A1MAPTL3MBTL1HPGD
SCHEMBL4357485 0.88 DCTPP1 (0.78) DCTPP1ALDH1A1MAPTL3MBTL1HPGD
SCHEMBL4357487 0.88 DCTPP1 (0.78) DCTPP1ALDH1A1MAPTL3MBTL1HPGD
SCHEMBL4357210 0.85 KMT2A (0.65) DCTPP1ALDH1A1MAPTHPGDKMT2A
SCHEMBL4357214 0.85 KMT2A (0.65) DCTPP1ALDH1A1MAPTHPGDKMT2A
SCHEMBL4355593 0.84 MAPT (0.61) DCTPP1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4355588 0.84 MAPT (0.61) DCTPP1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4354199 0.80 ALDH1A1 (1.00) DCTPP1ALDH1A1MAPTHPGDKMT2A
SCHEMBL4354203 0.80 ALDH1A1 (1.00) DCTPP1ALDH1A1MAPTHPGDKMT2A
SCHEMBL4354253 0.80 ALDH1A1 (0.78) DCTPP1ALDH1A1MAPTL3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 DCTPP1 167/4885ALDH1A1 284/4885MAPT 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.